Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
89 studies found for:    "Salivary Gland Neoplasms"
Show Display Options
RSS Create an RSS feed from your search for:
"Salivary Gland Neoplasms"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors
Conditions: Salivary Gland Tumors;   Head and Neck Cancer
Interventions: Drug: Docetaxel;   Radiation: Intensity-modulated radiotherapy;   Drug: Pemetrexed;   Drug: Cisplatin
2 Recruiting Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors
Conditions: Salivary Gland Tumors;   Head and Neck Cancer
Interventions: Drug: Cisplatin;   Drug: Docetaxel;   Radiation: Intensity-modulated radiotherapy
3 Completed A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Condition: Malignant Salivary Gland Tumors
Interventions: Drug: Cisplatin: 40 mg/m2 weekly during radiation;   Radiation: Radiation: 60-66 Gy in 2 Gy daily fractions
4 Recruiting Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers
Condition: Salivary Glands Tumors
Intervention: Drug: Abiraterone acetate
5 Completed Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor
Condition: Head and Neck Cancer
Interventions: Drug: carboplatin;   Drug: cisplatin;   Drug: gemcitabine hydrochloride
6 Recruiting Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
Condition: Head and Neck Cancer
Interventions: Drug: cisplatin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
7 Recruiting A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
Conditions: Salivary Gland Cancer;   Metastatic;   Advanced;   Recurrent
Interventions: Drug: Selinexor;   Drug: EGFR or HER2 Inhibitor;   Drug: FGFR Inhibitor;   Drug: C-KIT Inhibitor;   Drug: Anti-androgen;   Drug: NOTCH Inhibitor;   Drug: MEK or PI3K Inhibitor
8 Recruiting Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample
Conditions: Breast Cancer;   Stomach Neoplasms;   Salivary Gland Neoplasms;   Thyroid Cancer
Intervention:
9 Withdrawn Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Conditions: Adenoma, Pleomorphic;   Mixed Salivary Gland Tumor;   Salivary Gland Tumor, Mixed;   Syringoma, Chondroid
Interventions: Radiation: Radiation;   Drug: Panitumumab
10 Recruiting Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14
Condition: Salivary Gland Cancers
Intervention: Drug: Axitinib
11 Recruiting Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer
Condition: Salivary Gland Cancer
Interventions: Radiation: brachytherapy;   Radiation: IMRT
12 Recruiting Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
Condition: Salivary Gland Cancer
Interventions: Drug: bicalutamide + triptorelin;   Drug: Cisplatin + Doxorubicin;   Drug: Carboplatin + Paclitaxel
13 Unknown  Activity of Sorafenib in Salivary Gland Cancer
Condition: Salivary Gland Cancer
Intervention: Drug: Sorafenib
14 Active, not recruiting Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
Conditions: Recurrent Salivary Gland Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer
Intervention: Drug: eribulin mesylate
15 Completed Iressa Study in Patients With Salivary Gland Cancer
Condition: Salivary Gland Cancer
Intervention: Drug: Gefitinib
16 Active, not recruiting
Has Results
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Conditions: High-grade Salivary Gland Mucoepidermoid Carcinoma;   Low-grade Salivary Gland Mucoepidermoid Carcinoma;   Recurrent Salivary Gland Cancer;   Salivary Gland Acinic Cell Tumor;   Salivary Gland Adenocarcinoma;   Salivary Gland Adenoid Cystic Carcinoma;   Salivary Gland Anaplastic Carcinoma;   Salivary Gland Malignant Mixed Cell Type Tumor;   Salivary Gland Poorly Differentiated Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Salivary Gland Cancer
Interventions: Drug: dasatinib;   Other: laboratory biomarker analysis
17 Completed Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
Conditions: High-grade Salivary Gland Carcinoma;   High-grade Salivary Gland Mucoepidermoid Carcinoma;   Low-grade Salivary Gland Carcinoma;   Low-grade Salivary Gland Mucoepidermoid Carcinoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Salivary Gland Cancer;   Salivary Gland Acinic Cell Tumor;   Salivary Gland Adenocarcinoma;   Salivary Gland Adenoid Cystic Carcinoma;   Salivary Gland Malignant Mixed Cell Type Tumor
Interventions: Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis
18 Active, not recruiting Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck
Condition: Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck
Intervention: Drug: BIBF1120
19 Active, not recruiting Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma
Condition: Salivary Gland Carcinoma
Intervention: Drug: pazopanib
20 Unknown  Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Salivary Gland Cancer That Cannot Be Removed By Surgery
Condition: Head and Neck Cancer
Interventions: Drug: capecitabine;   Drug: oxaliplatin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.